Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma | MicrobiomeTrials← Back to trialsNCT07891923
Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-10-28Est. Completion: 2029-05-05
Enrollment target: 52 participants Locations- Actrec Tmc, Navi Mumbai, Maharashtra, India
- Dr.Sumeet Mirgh, Navi Mumbai, Maharashtra, India
Other microbiome trials you might be interested in
Multiple Myeloma
The goal of this clinical trial is to evaluate whether CM336, a BCMA/CD3 bispecific antibody, in combination with daratu…
Tianjin, ChinaEst. completion Apr 15, 2029
Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)
Background:
Multiple myeloma (MM) is an incurable cancer of certain blood cells. MM often returns after treatment, and …
Bethesda, United StatesEst. completion Dec 6, 2027